greeksoup/ stock research

OptimizeRx Corp.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 12 May 2026: press release. Guidance figures: 1 lowered, 2 new, 1 kept. The quarter’s numbers.

Key takeaways

  • Revenue fell 10% year on year: Revenue was $19.8 million, against $21.9 million in the first quarter of 2025. The company reported the change as a 10% decline. Source
  • Adjusted EBITDA rose to $3.3 million: Adjusted EBITDA was $3.3 million, against $1.5 million a year earlier. Adjusted EBITDA is a non-GAAP measure reconciled in the release. Source
  • MFN pricing disrupts customer spending: Management said ongoing MFN pricing dynamics and other macroeconomic factors are causing short to intermediate term disruption and more measured customer spending. Source
  • Term loan principal repaid: The company repaid $2.7 million of term loan principal in the quarter, against $500,000 a year earlier. It ended the quarter with $23.6 million of debt. Source
  • EHR network opened to DSPs: The company is opening its proprietary electronic health record network to demand-side platforms, so media buyers can run point-of-care campaigns within programmatic workflows. Source
  • Efficiency initiatives launched: After quarter end, operating efficiency initiatives were launched, with expected annualized savings of $3 million, including $1 million in 2026. Source

“We delivered a solid start to 2026, exceeding consensus for the quarter, reinforcing the strength and resilience of our operating model.”

Stephen Silvestro, OptimizeRx CEO

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFiscal year 2026$95 million to $100 millionLowered from $109 million to $114 million
Adjusted EBITDA SourceFiscal year 2026$21 million to $25 millionKept
Annual interest expense savings SourceAnnual, following the refinancingapproximately $1.5 millionNew
Operating efficiency savings SourceAnnualized, with $1 million in 2026$3 million annualizedNew

What changed from last quarter

  • Guidance lowered: Fiscal 2026 revenue guidance was updated to $95 million to $100 million, from $109 million to $114 million in the March 2026 release. Source
  • Guidance kept: Fiscal 2026 adjusted EBITDA guidance was kept at $21 million to $25 million. Source
  • New: The company refinanced its debt with Fifth Third Bank through a $25 million term loan and an undrawn $10 million revolver after quarter end. Source
  • New: After quarter end, operating efficiency initiatives were launched, with expected annualized savings of $3 million. Source
  • New: The company is opening its proprietary electronic health record network to demand-side platforms, which media buyers can use for point-of-care campaigns. Source
  • New: The top 20 pharmaceutical manufacturers definition used in the key performance indicators was updated, and prior periods were restated. Source

Results and profitability

  • Revenue fell 10% year on year: Revenue was $19.8 million, against $21.9 million in the first quarter of 2025. The company reported the change as a 10% decline. Source
  • Adjusted EBITDA rose to $3.3 million: Adjusted EBITDA was $3.3 million, against $1.5 million a year earlier. Adjusted EBITDA is a non-GAAP measure reconciled in the release. Source
  • GAAP loss narrowed, non-GAAP income rose: GAAP net loss was $(0.5) million, or $(0.03) per diluted share, against $(2.2) million, or $(0.12). Non-GAAP net income was $2.7 million, or $0.14 per diluted share, against $1.5 million, or $0.08. Source

Customers and key metrics

  • Top 20 manufacturers' revenue share fell: The top 20 pharmaceutical manufacturers made up 52% of rolling twelve-month revenue, against 63% a year earlier. The company updated the list the group is drawn from. Source
  • Average revenue per top 20 client lower: Average revenue per top 20 manufacturer was $2.79 million over the rolling twelve months, against $2.96 million. Prior periods were restated for the updated list. Source
  • Net revenue retention and staff productivity: Net revenue retention was 110%, against 114%. Revenue per average full-time employee was $801,000, against $710,000 a year earlier. Source

“While we are seeing some short to intermediate term disruption from ongoing most favored nations (MFN) pricing dynamics and other macroeconomic factors leading to more measured customer spending, we do not view these pressures as enduring obstacles.”

Stephen Silvestro, OptimizeRx CEO

Costs and margins

  • Cost of revenues fell to $4.9 million: Cost of revenues, excluding depreciation and amortization, was $4.9 million against $8.6 million a year earlier. Revenue fell 10% over the same comparison. Source
  • Operating expense lines moved: General and administrative expenses were $3.5 million, against $4.6 million, and sales and marketing was $4.7 million, against $5.0 million. Research and development rose to $3.4 million, and stock-based compensation to $1.8 million. Source
  • Income from operations turned positive: Total expenses were $19.4 million, against $24.0 million, leaving income from operations of $396,000 against a $2.1 million loss a year earlier. Source

Demand and pricing pressure

  • MFN pricing disrupts customer spending: Management said ongoing MFN pricing dynamics and other macroeconomic factors are causing short to intermediate term disruption and more measured customer spending. Source
  • Pressures not seen as enduring: Management said it does not see these pressures as enduring obstacles, and that digital, data-driven engagement remains a meaningful driver for the business. Source
  • Traction outside MFN-affected accounts: Management cited traction with existing customers not directly affected by MFN, and with mid-tier and emerging clients. Source

“We are encouraged by the traction we are seeing with existing customers, particularly in instances where they are not directly impacted by MFN, and with mid-tier and emerging clients.”

Stephen Silvestro, OptimizeRx CEO

Cash, debt and interest

  • Cash balance declined: Cash and cash equivalents were $20.2 million at March 31, 2026, against $23.4 million at December 31, 2025. Net cash used in operating activities was $467,000. Source
  • Term loan principal repaid: The company repaid $2.7 million of term loan principal in the quarter, against $500,000 a year earlier. It ended the quarter with $23.6 million of debt. Source
  • Receivables and payables fell: Accounts receivable fell to $32.0 million from $37.8 million, accrued expenses to $3.6 million from $11.6 million, and revenue share payable to $955,000 from $3.1 million. Source
  • Interest paid lower: Interest expense was $1.2 million, against $1.3 million a year earlier. Cash paid for interest was $798,000, against $1.1 million. Source

Platform and efficiency

  • EHR network opened to DSPs: The company is opening its proprietary electronic health record network to demand-side platforms, so media buyers can run point-of-care campaigns within programmatic workflows. Source
  • Efficiency initiatives launched: After quarter end, operating efficiency initiatives were launched, with expected annualized savings of $3 million, including $1 million in 2026. Source
  • Programmatic access as future channel: Management expects programmatic DSP access to raise inventory utilization and open a new high-growth channel over time, with no date given. Source

Coming up, as management said on 12 May 2026

  • Individual meetings with management: Management has set aside time for individual meetings with portfolio managers and analysts, arranged through the named contacts. Source

Figures management reported

FigureReported
Average revenue per top 20 pharmaceutical manufacturers (rolling twelve months) Source$2,791 thousand, against $2,963 thousand
Percent of total revenue from top 20 pharmaceutical manufacturers (rolling twelve months) Source52%, against 63%
Net revenue retention (rolling twelve months) Source110%, against 114%
Revenue per average full-time employee (rolling twelve months) Source$801 thousand, against $710 thousand

Risks management discussed

  • Demand: Management said MFN pricing dynamics are causing short to intermediate term disruption to customer spending. Source
  • External: Management cited other macroeconomic factors as contributing to more measured customer spending. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.